唐艷旻女士是啟明創(chuàng)投投資合伙人，專注于醫(yī)療健康領(lǐng)域的投資。
加入啟明創(chuàng)投前，唐艷旻女士在晨興創(chuàng)投工作13年(2002-2015)，擔(dān)任晨興北京辦公室負(fù)責(zé)人。在此期間，獨(dú)立投資并在董事會(huì)層面管理超過20家早期生物醫(yī)藥公司。其中大部分均已通過上市或并購?fù)緩匠晒ν顺?，回?bào)豐厚。
加入晨興之前，唐艷旻女士在葛蘭素史克工作七年，其中有五年時(shí)間負(fù)責(zé)新藥注冊(cè)工作，兩年時(shí)間任職產(chǎn)品經(jīng)理。
唐艷旻女士在中國科學(xué)院獲得碩士學(xué)位，在沈陽藥科大學(xué)獲得學(xué)士學(xué)位，并在長江商學(xué)院完成高級(jí)工商管理課程的學(xué)習(xí)，獲得碩士學(xué)位。
?
Ms. Amy Tang is a Venture Partner at Qiming Venture Partners.?
Amy previously worked in Morningside Ventures for 13 years (2002~2015). in charge of its Beijing office. Amy invested and managed dozens of early stage biotech portfolios during this period. Up till now, most of the investments have exited via IPOs or M&A with multiple returns.
Prior to joining Morningside, Amy worked in GSK as a regulatory manager for five years and product manager for two years.
Amy earned her master's degree in Chinese Academy of Sciences and a bachelor's degree from Shen Yang Pharmaceutical University. Amy is also a graduate of EMBA course of?Cheung Kong Graduate School of Business (CKGSB).
?